Flare Therapeutics is a biotechnology company that develops small molecule medicines targeting transcription factors to treat diseases driven by genetic mutations. The company utilizes innovative approaches to identify druggable regions on transcription factors, known as switch sites, to advance its drug discovery pipeline. Flare's research initially focuses on precision oncology, with aspirations to extend into neurology, rare genetic disorders, immunology, and inflammation. The team at Flare emphasizes collaboration, creativity, and a deep commitment to scientific exploration, while fostering a diverse and inclusive culture supportive of various perspectives and experiences. The company's mission is to transform the understanding of transcription factors into transformative therapies, all while prioritizing the well-being of patients.